3-amino-2-carbomethoxythieno[3,2-b]pyridine-4-oxide | 181283-64-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 3-amino-2-carbomethoxythieno[3,2-b]pyridine-4-oxide
• 英文别名: methyl 3-amino-4-oxidothieno[3,2-b]pyridin-4-ium-2-carboxylate
• CAS: 181283-64-7
• 化学式: C₉H₈N₂O₃S
• 分子量: 224.24
• InChiKey: KTJKWIWRBIWNFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-amino-2-carbomethoxythieno[3,2-b]pyridine-4-oxide 在 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 2.75h， 生成 Methyl 7-chloro-3-isocyanatothieno[3,2-b]pyridine-2-carboxylate
  参考文献：
  名称：

  Structure−Activity Studies for a Novel Series of Tricyclic Substituted Hexahydrobenz[e]isoindole α_1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)

  摘要：

  In search of a uroselective agent that exhibits a high level of selectivity for the alpha(1A) receptor, a novel series of tricyclic hexahydrobenz[e]isoindoles was synthesized. A generic pharmacophoric model was developed requiring the presence of a basic amine core and a fused heterocyclic side chain separated by an alkyl chain. It was shown that the 6-OMe substitution with R, R stereochemistry of the ring junction of the benz[e]isoindole and a two-carbon spacer chain were optimal. In contrast to the highly specific requirements for the benz[e]isoindole portion and linker chain, a wide variety of tricyclic fused heterocyclic attachments were tolerated with retention of potency and selectivity. In vitro functional assays for the alpha(1) adrenoceptor subtypes were used to further characterize these compounds, and in vivo models of vascular vs prostatic tone were used to assess uroselectivity.

  DOI：

  10.1021/jm990567u
• 作为产物：
  描述：

  3-氯-2-氰基吡啶 在 双氧水 、 sodium methylate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 3-amino-2-carbomethoxythieno[3,2-b]pyridine-4-oxide
  参考文献：
  名称：

  Structure−Activity Studies for a Novel Series of Tricyclic Substituted Hexahydrobenz[e]isoindole α_1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)

  摘要：

  In search of a uroselective agent that exhibits a high level of selectivity for the alpha(1A) receptor, a novel series of tricyclic hexahydrobenz[e]isoindoles was synthesized. A generic pharmacophoric model was developed requiring the presence of a basic amine core and a fused heterocyclic side chain separated by an alkyl chain. It was shown that the 6-OMe substitution with R, R stereochemistry of the ring junction of the benz[e]isoindole and a two-carbon spacer chain were optimal. In contrast to the highly specific requirements for the benz[e]isoindole portion and linker chain, a wide variety of tricyclic fused heterocyclic attachments were tolerated with retention of potency and selectivity. In vitro functional assays for the alpha(1) adrenoceptor subtypes were used to further characterize these compounds, and in vivo models of vascular vs prostatic tone were used to assess uroselectivity.

  DOI：

  10.1021/jm990567u

文献信息

• Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic
  申请人：Abbott Laboratories

  公开号：US05597823A1

  公开（公告）日：1997-01-28

  The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a tricyclic heterocyclic ring system; which is an .alpha.-1 adrenergic antagonist and is useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.

  本发明涉及一种具有以下结构的化合物##STR1##及其药用可接受的盐，其中W是一个三环杂环环系统；它是一种α-1肾上腺素受体拮抗剂，对治疗BPH有用；还公开了α-1拮抗剂组合物和拮抗α-1受体并治疗BPH的方法。
• [EN] TRICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS<br/>[FR] ANTAGONISTES ALPHA-1-ADRENERGIQUES D'HEXAHYDROBENZEISOINDOL TRICYCLIQUE SUBSTITUE
  申请人：ABBOTT LABORATORIES

  公开号：WO1996022992A1

  公开（公告）日：1996-08-01

  (EN) The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a tricyclic heterocyclic ring system; which is an $g(a)-1 adrenergic antagonist and is useful in the treatment of BPH; also disclosed are $g(a)-1 antagonist compositions and a method for antagonizing $g(a)-1 receptors and treating BPH.(FR) La présente invention concerne un composé, ainsi que ses sels acceptables sur le plan pharmaceutique, correspondant à la formule (I) où W est un système de noyau hétérocyclique tricyclique. Ce composé est un antagoniste $g(a)-1 adrénergique utile dans le traitement de l'hyperplasie prostatique bénigne. Cette invention concerne également des compositions à base d'antagoniste $g(a)-1 ainsi qu'un procédé visant à rendre antagonistes des récepteurs $g(a)-1, et utilisé dans le traitement de l'hyperplasie prostatique bénigne.

  本发明涉及化合物(I)及其在药学上可接受的盐，其中W是三环杂环环系统；该化合物是$g(a)-1肾上腺素受体拮抗剂，用于治疗BPH；此外还揭示了$g(a)-1拮抗剂组合物以及拮抗$g(a)-1受体和治疗BPH的方法。
• TRICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS
  申请人：Abbott Laboratories

  公开号：EP0808318B1

  公开（公告）日：2000-06-28
• US5597823A
  申请人：——

  公开号：US5597823A

  公开（公告）日：1997-01-28
• Structure−Activity Studies for a Novel Series of Tricyclic Substituted Hexahydrobenz[<i>e</i>]isoindole α_1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
  作者：Michael D. Meyer、Robert J. Altenbach、Fatima Z. Basha、William A. Carroll、Stephen Condon、Steven W. Elmore、James F. Kerwin、Kevin B. Sippy、Karin Tietje、Michael D. Wendt、Arthur A. Hancock、Michael E. Brune、Steven A. Buckner、Irene Drizin

  DOI：10.1021/jm990567u

  日期：2000.4.1

  In search of a uroselective agent that exhibits a high level of selectivity for the alpha(1A) receptor, a novel series of tricyclic hexahydrobenz[e]isoindoles was synthesized. A generic pharmacophoric model was developed requiring the presence of a basic amine core and a fused heterocyclic side chain separated by an alkyl chain. It was shown that the 6-OMe substitution with R, R stereochemistry of the ring junction of the benz[e]isoindole and a two-carbon spacer chain were optimal. In contrast to the highly specific requirements for the benz[e]isoindole portion and linker chain, a wide variety of tricyclic fused heterocyclic attachments were tolerated with retention of potency and selectivity. In vitro functional assays for the alpha(1) adrenoceptor subtypes were used to further characterize these compounds, and in vivo models of vascular vs prostatic tone were used to assess uroselectivity.